West Oak Capital’s NovoCure NVCR Stock Holding History

West Oak Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$23K	–	380
2021 Q3	$23K	Hold	200	–	–	0.01%	234
2021 Q2	$44K	Hold	200	–	–	0.02%	193
2021 Q1	$26K	Hold	200	–	–	0.01%	217
2020 Q4	$35K	Hold	200	–	–	0.02%	197
2020 Q3	$22K	Hold	200	–	–	0.01%	192
2020 Q2	$12K	Hold	200	–	–	0.01%	232
2020 Q1	$13K	Buy	+200	New	+$15.8K	0.01%	215

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

West Oak Capital's NVCR Position: Q4 2021 in Review

West Oak Capital sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 200 shares — an estimated $23K sold.

West Oak Capital first reported a position in NVCR in Q1 2020 and held it in 7 quarters. The position peaked at $44K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

West Oak Capital reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
West Oak Capital sold 200 NovoCure shares in Q4 2021, an estimated $23K.
West Oak Capital first reported a position in NovoCure in Q1 2020 and held it in 7 quarters.
West Oak Capital's NovoCure position peaked at $44K in Q2 2021.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on West Oak Capital's 13F filing for Q4 2021, filed 12 Jan 2022.